Evidence map›Paper›PMID 42301522›Full record

ArticleActa neuropathologica2026

Neuropathological study of the effects of aducanumab anti-Aβ immunotherapy on patients with Alzheimer's disease.

Lindsay A Welikovitch, Derek H Oakley, Rachel E Bennett, Alberto Serrano-Pozo, Haoyang Zhu, Nancy E Ruiz-Uribe, Theodore J Zwang, Lori B Chibnik, Teresa Gomez-Isla, Matthew P Frosch and 12 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta neuropathologica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Lindsay A WelikovitchDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Derek H OakleyHarvard Medical School, Boston, MA, 02115, USA.
Rachel E BennettDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Alberto Serrano-PozoDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Haoyang ZhuDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Nancy E Ruiz-UribeDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Theodore J ZwangDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Lori B ChibnikDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, 02115, USA.
Teresa Gomez-IslaDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Matthew P FroschDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA.
Donald S MarksHeadlands Research Eastern MA, Plymouth, MA, 02360, USA.
Stephen SallowayWarren Alpert Medical School of Brown University, Providence, RI, 02906, USA.
Charles BernickCleveland Clinic Lou Ruvo Center for Brain Health - Las Vegas, Las Vegas, NV, 89106, USA.
David GreeleyKingfisher Cooperative, LLC, Spokane, WA, 99201, USA.
Caitlin S LatimerDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, 98115, USA.
Amber NolanDepartment of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, 98115, USA.
R Matthew HutchisonBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Carrie E RubelBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Thierry BussiereBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
Edward D PloweyBiogen, 225 Binney Street, Cambridge, MA, 02142, USA.
C Dirk KeeneUniversity of California San Diego, La Jolla, CA, 92093, USA.
Bradley T HymanDepartment of Neurology, Massachusetts General Hospital, Charlestown, MA, 02129, USA. bhyman@mgh.harvard.edu.

Funding

University of Washington Alzheimer's Disease Research CenterP30AG066509 · NIA · UNIVERSITY OF WASHINGTON · PI Amanda D. Boyd · 2020 to 2026
$29.0M
Microvascular Stress as a Pathway to Neurodegeneration in Alzheimer'sR01AG071567 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Rachel Elise Bennett · 2022 to 2026
$2.1M
Alzheimer's Association 24AARF-1192364Massachusetts Alzheimer Disease Research Center P30AG062421NIA NIH HHS P30 AG066509NIH HHS R01AG071567NIH HHS UW ADRC P30 AG066509US Department of Defense W81XWH-21-S-TBIPH2
6 · The paper itself

Abstract

Fluid and imaging biomarker data show that anti-amyloid (Aβ) antibodies promote the clearance of Aβ from the brains of patients with Alzheimer's disease (AD). We examined postmortem brain tissue of individuals who participated in aducanumab clinical trials and investigated the drug's effects on Aβ pathology and other AD phenotypes. The medial temporal lobe of six aducanumab clinical trial participants-who had extensive exposure to aducanumab and happened to die between 7 weeks and 5 years after their last antibody infusion-was compared with that of nine untreated AD patients matched for age, APOE genotype, and Braak neurofibrillary tangle stage, to determine how aducanumab impacts AD pathobiology. Patients treated with aducanumab displayed a robust reduction in Aβ burden. As observed in previous studies, Aβ was associated with non-arterial microvessels in aducanumab-treated patients, suggesting a redistribution of Aβ within the neuropil. Neuritic phospho-tau decreased in parallel with fewer Aβ plaques, but the density of PHF-1

Indexed as

Alzheimer DiseaseAmyloid beta-PeptidesAntibodies, Monoclonal, HumanizedBrainImmunotherapyAgedAged, 80 and overFemaleHumansMaleNeurofibrillary TanglesPlaque, Amyloidtau ProteinsaducanumabAmyloid beta-PeptidesAntibodies, Monoclonal, Humanizedtau Proteins

Identifiers

PMID42301522
PMCPMC13272220

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.